Pharmaceutical Container
Found 6 free book(s)
Guideline on Inhalational medicinal products
www.ema.europa.euPharmaceutical Development). 4.2 DRUG PRODUCT PHARMACEUTICAL DEVELOPMENT Pharmaceutical development studies are conducted to establish that the dosage form, formulation, manufacturing process, container closure system, microbiological attributes and instructions for use are appropriate and result in acceptable product performance.
<1151> PHARMACEUTICAL DOSAGE FORMS - DrugFuture
www.drugfuture.comDevelopment of a compendial Excess Volume in Injections—Each container of an Injec-taxonomy and glossary for pharmaceutical dosage forms. Pharm Forum. tion is filled with a volume in slight excess of the labeled 2003;29(5):1742–1752. “size” or the volume that is to be withdrawn. The excess Official from May 1, 2012
Q8 (R2) Step 5 Pharmaceutical Development
www.ema.europa.euICH guideline Q8 (R2) on pharmaceutical development Step 5 Transmission to CHMP December 2004 Transmission to interested parties December 2004 Deadline for comments June 2005 ... excipients, container closure systems, and manufacturing processes that are critical to product quality should be determined and control strategies justified. Critical ...
Annex 4 WHO guidelines for sampling of pharmaceutical ...
www.who.int— pharmaceutical products (in-process as well as before and after packaging); — primary and secondary packaging materials; and — cleaning and sanitizing agents, compressed gases and other pro-cessing agents. 1.5 Sampling facilities Sampling facilities should be designed to: — prevent contamination of the opened container, the materials and
Q8(R2) - ICH
database.ich.orgParent Guideline: Pharmaceutical Development Q8 Approval of the Guideline by the Steering Committee under Step 2 and release for public consultation. 18 ... excipients, container closure system, any relevant dosing device), the manufacturing process, and, if appropriate, knowledge gained from the development of similar drug ...
STABILITY TESTING OF ACTIVE SUBSTANCES AND …
www.who.intand the pharmaceutical excipients, the dosage form and its composition, the manufacturing process, the nature of the container-closure system, and the properties of the packaging materials. Also, the stability of excipients that may contain or form reactive degradation products, have to be considered.